Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Autores
GUTIC, Bojana
BOZANOVIC, Tatjana
MANDIC, Aljosa
DUGALIC, Stefan
TODOROVIC, Jovana
DUGALIC, Miroslava Gojnic
SENGUL, Demet
SENGUL, Ilker
DETANAC, Dzemail
KESICIOGLU, Tugrul
Citação
CLINICS, v.78, article ID 100204, 5p, 2023
Resumo
Objective: The present study purposed to determine characteristics of ovarian carcinoma and to analyze predictors of survival in patients with ovarian carcinoma. Method: A retrospective cohort study was conducted including the patients with diagnosed ovarian carcinoma treated at the Clinic for Operative Oncology, Oncology Institute of Vojvodina in the period from January 2012 to December 2016. Seventy-two women with ovarian carcinoma were included in the analysis. The data about the histological type of tumor, disease stage, treatment, lymphatic infiltration, and surgical procedure were collected retrospectively, using the database of the institution where the research was conducted (BirPis 21 SRC Infonet DOO - Information System Oncology Institute of Vojvodina). Descriptive statistics and multivariate analysis using Cox proportional hazards model were performed. Results: The univariate Cox regression analysis identified histology, tumor grade, FIGO (International Federation of Gynecology and Obstetrics) stage, NACT (Neoadjuvant Chemotherapy), number of therapy cycles, type of surgery, and chemotherapy response as independent predictors of mortality. Finally, the type of tumor and chemotherapy response had an increased hazard ratio for mortality in the multivariate Cox regression model. Herewith, the percentage of high-grade, advanced-stage ovarian cancer patients with complete response to chemotherapy, absence of recurrent disease, and lymphovascular space invasion were significant predictors of survival in patients with ovarian carcinoma. Conclusions: Herein, emerging data regarding precision medicine and molecular-based personalized treatments are promising and will likely modify the way the authors provide multiple lines of treatments in the near future.
Palavras-chave
Ovary, Carcinoma, Oncology, Histopathology, Pathology
Referências
- Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019
- Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
- Centers for Disease Control and Prevention, 2009, US CANC STAT 1999 20
- Chen LM, 1998, CLIN OBSTET GYNECOL, V41, P200, DOI 10.1097/00003081-199803000-00025
- Didkowska J., 2021, CANC POLAND 2019
- Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
- Dood RL, 2018, JAMA ONCOL, V4, P1519, DOI 10.1001/jamaoncol.2018.2761
- Grody WW, 2007, HENRYS CLIN DIAGNOSI, P1334
- Gutic B, 2023, CLINICS, V78, DOI 10.1016/j.clinsp.2023.100177
- Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7
- Kessous R, 2021, INT J CANCER, V148, P2304, DOI 10.1002/ijc.33395
- Kim SI, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100149
- Kisch E, 2005, ANN INTERN MED, V143, P547, DOI 10.7326/0003-4819-143-7-200510040-00025
- Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011
- Li J, 2017, ONCOTARGET, V8, P9672, DOI 10.18632/oncotarget.14192
- Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242
- Moslehi R, 2000, AM J HUM GENET, V66, P1259, DOI 10.1086/302853
- Nair D, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00407
- Peres LC, 2020, GYNECOL ONCOL, V156, P459, DOI 10.1016/j.ygyno.2019.12.011
- Piao J, 2020, OBSTET GYNECOL SCI, V63, P346, DOI 10.5468/ogs.2020.63.3.346
- Reid BM, 2017, CANCER BIOL MED, V14, P9, DOI 10.20892/j.issn.2095-3941.2016.0084
- Sengul D, 2021, NORTH CLIN ISTANB, V8, P644, DOI 10.14744/nci.2021.78466
- Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
- Vo C, 2007, OBSTET GYN CLIN N AM, V34, P687, DOI 10.1016/j.ogc.2007.09.008
- Whiteman DC, 2003, CANCER EPIDEM BIOMAR, V12, P42